The present invention relates to the method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I) ##STR1## to the said mammal. Compound (I) can be used for the therapy and prophylaxis of cardiovascular diseases like stable and unstable angina pectoris, Prinzmetal angina (spasm), acute coronary syndrome, heart failure, myocardial infarction, stroke, ...

An agricultural germicide having the formula ##SPC1## Wherein R represents C.sub.1-12 alkyl, alkenyl, alkynyl, benzyl or chlorobenzyl.

This inventions relates to a method of treating malignant tumors of the pancreatic, colic or gastric origin whose growth is increase by bioactive polypeptides comprising administering an anti-tumor effective amount of proglumide or pharmaceutical acceptables salt thereof to a patient afflicted with said malignant tumors.

The present invention relates to the method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I) ##STR1## to the said mammal. The compound (I) can be used for the therapy and prophylaxis of cardiovascular diseases like stable and unstable angina pectoris, Prinzmetal angina (spasm), acute coronary syndrome, heart failure, myocardial infarction, stro...

This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.

This invention relates to certain aminobenzanilide compounds, and to the use, in the treatment of mammals, of certain aminobenzanilide compounds as anticonvulsant agents.

Method of treating demyelinating diseases such as multiple sclerosis by treatment with colchicine or colchiceine.

A composition comprising from 0.02 to 17 parts by weight of glycerol per part by weight of an iron chelating agent selected from the group consisting of salicyl hydroxyamic acid; 2,3- and 3,4-dihydroxy benzoic acid; and halobenzohydroxamic; e.g., m-iodobenzohydroxamic acid and m-chlorobenzohydroxamic acid; as well as their C.sub.1 to C.sub.4 alkyl esters. When this composition is administered parenterally, it is found to block aerobic and anaerobic glucose catabolism and thereby accomplish contr...

CINNAMAMIDE compounds of the formula ##STR1## where X is chloro, bromo or iodo and R is hydrogen or alkyl of 1 to 3 carbons as pharmaceuticals which are useful in the treatment or prophylaxis for convulsions.

A method of administering N-substituted benzamides, and their acid addition salts, in particular metoclopramide and its acid addition salts, is disclosed wherein the metoclopramide or acid addition salt is injected intramuscularly in a formulation with a pH of about 5.5 to about 7.0 and at a concentration of at least about 50 mg/ml, to deliver a dose of one to 5 mg/kg.